Although so far, there are no clinical data available on the impact of BRCA mutations or homologous repair deficiency (HRD) on anti-PD-L1 monotherapy efficacy in ovarian cancer, results from the combination therapy with PARP inhibitors indicate that the benefit of adding ICB might be higher in BRCA wild-type tumours [28–30]. The gene discussed is CD274; the disease is ovarian carcinoma.